Biocontainment Research support services core

生物遏制研究服务：摘要 NIAID资助的12个区域生物遏制实验室(RBL)中的每一个都有 区分和补充研究能力，以促进传染病和 生物防御研究。乔治梅森大学的S博士，也被称为生物医学 研究实验室(BRL)专注于芯片上器官的集成和开发 (OOC)模型在体外桥接治疗和动物模型试验中的应用 疫苗产品筛选和评价。此外，GMU拥有一套全面的 支持BSL-3病原体和选择气雾剂的先进研究仪器 小动物暴露以及器官、组织和分子水平的挑战分析 学习。这些遏制能力得到了GMU在以下方面的专业知识的补充 蛋白质组学、代谢组学和纳米技术，以及开发平台的记录 已经从替补席过渡到市场的技术。 GMU拟议的生物遏制研究支持服务核心将包括1) 微生理系统(MPS)核心和2)高级动物研究(AAR)核心。 MPS平台将代表至少九个不同的器官系统，由 至少12种优先病毒和细菌病原体的相关人类来源细胞类型。 伴随分析包括病原体定量、炎症性 将为每种模型开发感染背景下的负担和器官损害。 核心中集成了额外的高吞吐量单芯片器官(OOC)和有机平台 将提供更多功能，通过多个平台验证结果，并加速 发现号。AAR核心将集成一套全面的最先进的技术和 传染病专业知识通过尖端技术加快应对措施开发 铅的优化、剂量、毒性筛选、安全性评估、有效性、免疫力的方法 调制和生物分配。 核心将配备BRL的研究科学家，以支持内部调查人员和 作为RBL网络和制药和生物技术合作伙伴的资源 公司；联邦、州和地方机构；以及学术机构 疾病与生物防御研究与对策发展。

BIOCONTAINMENT RESEACRCH SERVICES: ABSTRACT Each of the twelve NIAID funded Regional Biocontainment Laboratories (RBLs) have distinguishing and complementary research capabilities to advance infectious disease and biodefense research. George Mason University’s (GMU)’s RBL, also known as the Biomedical Research Laboratory (BRL) has focused on the integration and development of organ-on-a-chip (OOC) models in containment to bridge in vitro and animal model testing for therapeutics and vaccine product screening and evaluation. Furthermore, GMU has a comprehensive suite of advanced research instrumentation to support BSL-3 pathogen and select agent aerosol exposures in small animals as well as organ, tissue, and molecular level analysis of challenge studies. These capabilities in containment are complemented by GMU’s expertise in proteomics, metabolomics, and nanotechnology as well as a track record of developing platform technologies that have transitioned from the bench to market. The proposed Biocontainment Research Support Services Core at GMU will include 1) a Microphysiological systems (MPS) core and 2) an Advanced Animal Research (AAR) core. The MPS platforms will represent at least nine different organ systems with representation by relevant human-derived cell types for at least twelve priority viral and bacterial pathogens. Accompanying assays including the limit of detection for pathogen quantification, inflammatory burden, and organ damage in the context of infection will be developed for each model. Additional high throughput organ-on-a-chip (OOC) and organoid platforms integrated in the core will provide added functionality, validation of results through multiple platforms, and accelerated discovery. The AAR core will integrate a comprehensive set of state-of-the-art technologies and infectious disease expertise to accelerate countermeasure development through cutting-edge approaches for lead optimization, dosing, toxicity screens, safety assessment, efficacy, immune modulation, and biodistribution. The cores will be staffed with research scientists in the BRL to support internal investigators and serve as a resource for the RBL network and partners from pharmaceutical and biotechnology companies; federal, state, and local agencies; and academic institutions conducting infectious disease and biodefense research and countermeasure development.